3,4-Dihydro-2H-1,4-benzoxazine → HCID 136352203, compound

HRID 880116Notes

Reaction equation

HRID 880116 reaction equation
[N:1]1([C:7]2[N:8]=[C:9]([CH2:14][C:15]([O-:17])=O)[NH:10][C:11](=[O:13])[CH:12]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.[Na+].[O:19]1[C:24]2[CH:25]=[CH:26][CH:27]=[CH:28][C:23]=2[NH:22][CH2:21][CH2:20]1>>[O:19]1[C:24]2[CH:25]=[CH:26][CH:27]=[CH:28][C:23]=2[N:22]([C:15](=[O:17])[CH2:14][C:9]2[NH:10][C:11](=[O:13])[CH:12]=[C:7]([N:1]3[CH2:2][CH2:3][O:4][CH2:5][CH2:6]3)[N:8]=2)[CH2:21][CH2:20]1

Participants

3

Reactant 2

HCID 5850963,4-Dihydro-2H-1,4-benzoxazineHCID 136041844Sodium (4-morpholin-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)acetate

Product 1

HCID 136352203HCID 136352203, compound

Procedure

The product is prepared according to the procedure described in Example 5, using 260 mg of sodium [4-(morpholin-4-yl)-6-oxo-1,6-dihydropyrimidin-2-yl]acetate and 270 mg of 3,4-dihydro-2H-1,4-benzoxazine in place of the 2,4-difluoroaniline. After purification by silica column chromatography, elution being carried out with CH2Cl2/MeOH 95/05, 150 mg of 2-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)-2-oxoethyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one are obtained in the form of a white solid, the characteristics of which are the following:

Workup

  1. customThe product is prepared
  2. customAfter purification
  3. washby silica column chromatography, elution
  4. customare obtained in the form of a white solid

Sources & evidence

ORD record
ord-88a034a41ac64c8b8de3ef1d3221de2f
Source dataset
uspto-grants-2015_03
Patent number
US08993565B2

Reaction notes

Loading…